First Patient Enrolled in AngioDynamics' RAPID Outcomes Database

August 6, 2015—AngioDynamics announced the enrollment of the first patient in the RAPID (Registry of AngioVac Procedures In Detail) database at the University of California-Los Angeles (UCLA) Health in Los Angeles, California. The RAPID database is designed to evaluate the patterns of use and safety and effectiveness data of the company’s AngioVac system in the en bloc removal of fresh, soft thrombi or emboli. The second-generation AngioVac device has received US Food and Drug Administration marketing clearance and is available in United States.

According to AngioDynamics, the primary objective of RAPID is to collect safety and effectiveness data on use of the AngioVac system for various anatomic locations. The investigators will capture a concise set of immediate and short-term functional and clinical outcome data for all patients who have the AngioVac catheter deployed into their venous system. Secondary objectives of the registry will be to study, assess, and benchmark clinical practice patterns by collecting selected process data for patients included in the registry. Data collected in this study may also be used to develop and refine standards of care for use of AngioVac and to facilitate the design of randomized clinical trials, stated the company.

RAPID’s National Principal Investigator is John M. Moriarty, MD, Assistant Professor of Radiology and Director of Cardiology-Interventional Radiology Innovation at UCLA. In the company’s announcement, Dr. Moriarty commented, “So far, we have centers in 31 states that want to take part in the registry. Our goal is to include as many potential collaborators as possible and start gathering much needed data regarding procedural and patient outcomes.”